CJC-1295 5MG
CJC-1295 5MG is a synthetic peptide designed for research applications in the field of endocrinology and metabolic studies. Known as a long-acting growth hormone-releasing hormone (GHRH) analog, CJC-1295 5MG has been studied for its ability to stimulate endogenous growth hormone (GH) secretion and influence downstream IGF-1 activity in controlled research settings.
Research Context
CJC-1295 5MG was developed for clinical and experimental investigation as a modified GHRH analog with an extended duration of action. In research settings, it is used to study pulsatile GH secretion, IGF-1 signaling, and broader endocrine responses related to metabolism, body composition, and tissue growth. Its prolonged activity has made it a useful compound for examining how sustained GHRH receptor stimulation differs from shorter-acting growth hormone secretagogues.
Research Overview
CJC-1295 5MG functions by binding to growth hormone-releasing hormone receptors and promoting the release of endogenous GH from the pituitary. Research has shown that it may increase circulating GH and IGF-1 levels while helping preserve the natural pulsatile pattern of GH secretion. This profile makes it a valuable tool in studies focused on hormone regulation, metabolic adaptation, and tissue response under controlled laboratory conditions.
Research has primarily explored its potential applications in endocrine dysfunction models, body composition studies, and investigations involving growth hormone axis modulation. Its use remains limited to research environments and experimental contexts.
Key Research Focus Areas
Endocrine Regulation Research: CJC-1295 5MG has been studied for its role in modulating the GH/IGF-1 axis and supporting investigations into pituitary signaling and hormone release patterns.
Metabolic Studies: Researchers have examined its effects on body composition, lipid metabolism, and broader metabolic processes in experimental models.
Muscle and Tissue Research: CJC-1295 5MG is used in studies assessing the relationship between GH signaling and changes in lean mass, tissue maintenance, and anabolic activity.
Comparative Peptide Research: Investigations have compared CJC-1295 5MG with other GHRH analogs and growth hormone secretagogues to better understand differences in duration, signaling, and physiological response.
Safety and Compliance
CJC-1295 5MG is intended solely for use in research environments under the direct supervision of qualified professionals. Due to its endocrine activity and potential systemic effects, it must be handled according to rigorous research standards, including proper documentation, storage, handling, and disposal procedures. Investigators should comply with all applicable institutional and regulatory requirements.
For research use only. Not for human or animal consumption.
| Size | 5MG |
|---|
